Vaginal Bleeding and Spotting: Causes, Risks, and Remedies

What is Vaginal Bleeding and Spotting?

Vaginal bleeding is any loss of blood through the vagina. The blood may originate from the uterus, the cervix, or the vaginal walls themselves. It can occur independently of the menstrual cycle, including during pregnancy, and in all these cases it warrants prompt medical evaluation by a gynecologist or general practitioner.

Vaginal bleeding is one of the most common gynecological symptoms, with approximately one in twenty women likely to experience it at some point in their lives outside of normal menstruation. The spectrum of causes is extraordinarily wide, ranging from entirely benign and self-limiting conditions to serious pathologies requiring urgent intervention.

It is important to emphasize from the outset that any bleeding occurring outside of the expected menstrual period should be medically evaluated, whether it presents as light spotting or as heavier bleeding. At the same time, many women are needlessly alarmed by the appearance of intermenstrual spotting: according to numerous sources, stress is one of the most common causes of mid-cycle spotting, and in the majority of cases no malignant cause is responsible.

What Is Spotting?

Spotting refers to very light, intermittent vaginal bleeding that is not sufficient to require the use of a sanitary pad or tampon. It typically appears as a few drops or a light smear of blood, often pinkish, brownish, or bright red, and may be noticed on underwear or toilet paper. While spotting is by definition lighter than a full menstrual flow, it deserves the same clinical attention as heavier bleeding, particularly if it is recurrent, unexplained, or associated with other symptoms.

How Does Vaginal Bleeding Present?

Vaginal bleeding most commonly presents as an isolated symptom. However, in some cases it may be accompanied by other manifestations that provide important clues to the underlying cause:

• Abdominal pain or pelvic pain
• Vaginal discharge
• Fatigue and general malaise
• Nausea and vomiting
• Pallor and tachycardia (as signs of significant blood loss and anemia)

The combination of these associated symptoms, together with the characteristics of the bleeding itself (volume, timing, color, consistency), forms the foundation of the clinical evaluation.

The Importance of Context

The significance of vaginal bleeding is highly context-dependent. A small amount of spotting shortly after a pelvic examination or following sexual intercourse in a young woman with a healthy cervix carries very different clinical implications from the same symptom occurring in a postmenopausal woman who has not menstruated in years. Similarly, any vaginal bleeding during pregnancy, however light, requires immediate medical assessment. This contextual approach, taking into account the patient’s age, reproductive status, medical history, and associated symptoms, is the backbone of gynecological evaluation.

---

Causes

The causes of vaginal bleeding are numerous and can be grouped into six major categories:

1. Complications of pregnancy (including unrecognized pregnancy):

   • Spontaneous abortion (miscarriage)
   • Ectopic pregnancy
   • Gestational trophoblastic disease (molar pregnancy)

2. Dysfunctional causes:

   • Anovulatory cycles
   • Polycystic ovary syndrome (PCOS)
   • Menorrhagia and metrorrhagia

3. Benign organic pathologies:

   • Uterine fibroids
   • Uterine polyps
   • Adenomyosis
   • Endometriosis
   • Genital infections

4. Malignant organic pathologies:

   • Endometrial cancer
   • Cervical cancer
   • Vaginal cancer
   • Sarcomas

5. General systemic causes:

   • Coagulation disorders
   • Leukemia
   • Hypothyroidism
   • Hepatic insufficiency
   • Renal insufficiency

6. Hormonal medications

Each of these categories is explored in detail in the sections that follow.

Spotting and the Contraceptive Pill

The appearance of spotting during the first few cycles of hormonal contraceptive use is extremely common and generally benign. This applies to women starting oral contraceptive pills as well as those who have recently had a hormonal intrauterine device (IUD) inserted.

The mechanism is straightforward: when exogenous (external) hormones are introduced, the endometrium (the uterine lining) must adapt to the new hormonal environment. During this adjustment period, which typically lasts one to three months, the endometrium may shed irregularly, producing breakthrough bleeding or spotting. This is sometimes called “withdrawal bleeding” or “breakthrough spotting”.

In the majority of women, this phenomenon resolves spontaneously as hormonal equilibrium is established, requiring no intervention beyond reassurance and monitoring. In a minority of cases, particularly if spotting persists beyond three to four months, the dose or formulation of the hormonal contraceptive may need to be adjusted. A gynecologist may recommend switching to a preparation with a slightly higher estrogen component to provide better endometrial support.

It is important to note that spotting does not reduce the contraceptive efficacy of the pill when the pill has been taken correctly and consistently.

Spotting and Bleeding During Pregnancy

Vaginal bleeding during pregnancy is a symptom that always warrants prompt medical attention, regardless of its apparent severity. The clinical implications and urgency vary considerably depending on the trimester in which it occurs.

First Trimester Bleeding

Light spotting during the first trimester (up to week 12) is common, occurring in approximately 20–25% of pregnancies, and in many cases it does not indicate a problem. Possible benign causes include:

• Implantation bleeding: Occurs when the fertilized egg implants into the uterine lining, typically 6–12 days after conception. This produces very light, brief spotting that some women mistake for a light period.
• Cervical sensitivity: The cervix becomes highly vascular during pregnancy and may bleed easily following sexual intercourse or a pelvic examination (contact bleeding).
• Cervical ectropion: A common, benign condition in which the inner lining of the cervical canal extends onto the outer surface of the cervix, making it more fragile and prone to bleeding.

However, first trimester bleeding can also signal more serious complications:

• Threatened miscarriage: Bleeding with or without cramping, while the cervix remains closed and the fetus is still viable. Requires rest and monitoring.
• Spontaneous abortion: Occurs in approximately 10–15% of known pregnancies. Bleeding is typically heavier and may be accompanied by tissue passage and cramping.
• Ectopic pregnancy: A potentially life-threatening condition in which the embryo implants outside the uterus, most commonly in a fallopian tube. Ectopic pregnancy can cause internal hemorrhage and constitutes a gynecological emergency.
• Gestational trophoblastic disease: A rare condition involving abnormal growth of trophoblastic tissue; may present with bleeding, exaggerated pregnancy symptoms, and an abnormally elevated hCG level.

Second and Third Trimester Bleeding

Bleeding in the second and third trimester (weeks 13–40) is less common but potentially more serious:

• Placenta previa: A condition in which the placenta partially or completely covers the internal cervical os (opening). Classically presents with painless, bright red vaginal bleeding, typically in the third trimester. Requires hospitalization and, usually, cesarean delivery.
• Placental abruption: Premature separation of the placenta from the uterine wall. Presents with sudden, often painful bleeding and represents an obstetric emergency requiring immediate intervention.
• Vasa previa: Fetal blood vessels run over or near the internal cervical os and are vulnerable to rupture when membranes break; can cause rapid fetal deterioration.
• Cervical or uterine pathology: Cervical polyps, cervicitis, or cervical cancer can all cause bleeding during pregnancy.
• Non-obstetric causes: Urinary tract infections or hemorrhoidal bleeding may be mistaken for vaginal bleeding.

Management of Bleeding in Pregnancy

The management approach depends on the severity of the bleeding, its timing within the pregnancy, and the associated clinical picture:

• Mild spotting: Careful observation, avoidance of sexual intercourse, rest, and close follow-up with the obstetrician.
• Significant bleeding: Hospitalization, continuous cardiotocographic monitoring of the fetus, and, if there is fetal distress or maternal hemodynamic instability, emergency cesarean section.

For a more detailed discussion, please refer to the dedicated article on vaginal bleeding in pregnancy.

Postpartum and Post-Abortion Bleeding

Heavy bleeding in the first weeks after delivery or following a miscarriage or termination may occur when:

• The uterus has not yet fully contracted back to its pre-pregnancy size (uterine atony).
• Retained products of conception (placental fragments or fetal tissue) remain within the uterine cavity, preventing complete uterine involution.

This condition, called postpartum hemorrhage or incomplete abortion with retained products, requires urgent gynecological management, which may include medical treatment (oxytocin, misoprostol) or surgical uterine evacuation.

Spotting and Menstrual Cycle Dysfunction

Menstrual cycle-related dysfunctions are among the most frequent causes of abnormal uterine bleeding in women of reproductive age.

Anovulatory Cycles

Anovulatory cycles are menstrual cycles in which ovulation does not occur. In a normal cycle, ovulation triggers the production of progesterone by the corpus luteum, which stabilizes the endometrium and ensures its orderly shedding at the end of the cycle. In the absence of ovulation, progesterone is not produced, and the endometrium, exposed to continuous, unopposed estrogen stimulation, proliferates excessively. When estrogen levels eventually fluctuate, the endometrium sheds irregularly, producing prolonged, irregular, and sometimes heavy bleeding that does not follow the expected menstrual pattern.

Underlying hormonal imbalances, disrupted FSH, LH, estrogen, or progesterone secretion, are at the root of anovulatory cycles and can be triggered by stress, rapid weight change, intense athletic training, eating disorders, thyroid disease, or other medical conditions.

Polycystic Ovary Syndrome (PCOS)

Polycystic ovary syndrome is one of the most common endocrine disorders affecting women of reproductive age, with a prevalence of approximately 8–13% worldwide. It primarily affects women between 20 and 40 years of age and is characterized by a constellation of features:

• Chronic anovulation: Leading to irregular or absent menstrual periods and infertility.
• Hyperandrogenism: Manifesting as hirsutism (excess hair growth), acne, and scalp hair thinning.
• Insulin resistance: Associated with an increased risk of developing type 2 diabetes mellitus and metabolic syndrome.
• Polycystic ovarian morphology: Multiple small follicles visible on ultrasound.

PCOS-related bleeding tends to be irregular and unpredictable, and the chronic, unopposed estrogen stimulation of the endometrium in untreated PCOS is also a risk factor for endometrial hyperplasia and, in the long term, endometrial cancer.

Menorrhagia

Menorrhagia refers to abnormally heavy and prolonged menstrual bleeding, defined clinically as blood loss exceeding 80 mL per cycle or lasting more than 7 days, that occurs at regular, predictable intervals. It is one of the most common gynecological complaints and can lead to significant iron-deficiency anemia and impairment of quality of life. Causes of menorrhagia include uterine fibroids, endometrial polyps, adenomyosis, coagulation disorders, and hormonal imbalances.

Metrorrhagia

Metrorrhagia refers to vaginal bleeding that occurs between expected menstrual periods, i.e., at irregular, unpredictable intervals. Unlike menorrhagia, which is heavy bleeding at the expected time, metrorrhagia is bleeding at the wrong time. It may be light or heavy, brief or prolonged, and warrants investigation to identify the underlying cause.

Stress, Eating Disorders, and Metabolic Causes

Stress, whether physical or psychological, has well-documented effects on the hypothalamic-pituitary-ovarian axis, which regulates the menstrual cycle. Chronic stress can disrupt the pulsatile release of GnRH, leading to irregular ovulation and abnormal bleeding patterns. Eating disorders such as anorexia nervosa and bulimia nervosa cause profound hormonal disruption through the mechanisms of energy deficiency and electrolyte imbalance. Metabolic conditions including metabolic syndrome, obesity, and thyroid disorders can all produce menstrual irregularity and intermenstrual bleeding.

Benign Organic Pathologies

Structural abnormalities of the uterus, ovaries, or cervix, most of them benign, are among the most frequent causes of abnormal uterine bleeding in women of reproductive age.

Uterine Fibroids (Leiomyomas)

Uterine fibroids are the most common benign uterine tumors, affecting up to 70–80% of women by the age of 50, though many are entirely asymptomatic. They are benign proliferations of smooth muscle cells within the uterine wall, ranging in size from millimeters to many centimeters. Fibroids that project into the uterine cavity (submucosal fibroids) are particularly likely to cause heavy and prolonged menstrual bleeding and intermenstrual spotting. Hormonal fluctuations, particularly elevated estrogen levels, drive fibroid growth.

Endometrial Polyps

Endometrial polyps are localized, benign overgrowths of endometrial glandular tissue and stroma that protrude into the uterine cavity. They are a very common cause of abnormal uterine bleeding in both premenopausal and postmenopausal women. Polyps may cause heavy menstrual bleeding, intermenstrual spotting, or postcoital bleeding, and they are best diagnosed by transvaginal ultrasound and confirmed by hysteroscopy. While most are benign, a small percentage, particularly in postmenopausal women, can harbor atypical or malignant changes.

Ovarian Cysts

Ovarian cysts are fluid-filled sacs within or on the surface of the ovary. Functional cysts (follicular and corpus luteum cysts) are common in women of reproductive age and are usually self-limiting. However, ovarian cysts can occasionally cause hormonal disturbances that result in irregular bleeding patterns, and large or ruptured cysts can cause pelvic pain and bleeding.

Adenomyosis

Adenomyosis is a condition in which endometrial glands and stroma invade the muscular wall of the uterus (myometrium), causing the uterus to enlarge and become “boggy”. This condition is most common in women over 35, particularly those who have had children, and is a major cause of dysmenorrhea (painful periods) and menorrhagia. The uterus may be diffusely or focally affected.

Endometriosis

Endometriosis is defined by the presence of endometrial-like tissue (glands and stroma) at sites outside the uterus, most commonly on the ovaries, fallopian tubes, peritoneum, and pelvic ligaments, but potentially also on the bladder, bowel, and even the lungs. These ectopic deposits respond to cyclical hormonal changes and bleed during menstruation, causing inflammation, scarring, and adhesions. The condition presents with pelvic pain (particularly dysmenorrhea), infertility, and abnormal bleeding patterns.

Cervical Ectropion (Cervical Erosion)

Cervical ectropion, sometimes colloquially referred to as a “cervical erosion,” is a benign condition in which the columnar epithelium of the inner cervical canal extends onto the outer surface of the cervix. This tissue is more delicate and more prone to bleeding than the surrounding squamous epithelium. Cervical ectropion is common in women of reproductive age, particularly those using estrogen-containing contraceptives, and may cause light, occasional spotting, especially after sexual intercourse or a cervical examination. It is generally benign and does not require treatment unless it causes troublesome symptoms.

Genital Infections

Genital infections can occasionally produce vaginal bleeding, though they more commonly manifest as abnormal vaginal discharge, odor, and pelvic pain. Sexually transmitted infections are particularly relevant:

• Chlamydia trachomatis: One of the most prevalent STIs worldwide. Often asymptomatic, but can cause cervicitis and intermenstrual or postcoital bleeding.
• Gonorrhea: Can cause cervicitis, with associated bleeding.
• Trichomonas vaginalis: Occasionally associated with cervical inflammation and contact bleeding.
• Bacterial vaginosis: Less commonly associated with bleeding, but the disruption of normal vaginal flora can contribute to cervical vulnerability.
• Pelvic inflammatory disease (PID): Ascending infection involving the uterus, fallopian tubes, and ovaries. Can cause intermenstrual bleeding, pelvic pain, and fever.

Malignant Organic Pathologies

Malignant causes of vaginal bleeding are significantly more common in the perimenopausal and postmenopausal period, though some can affect younger women, particularly cervical cancer, which is strongly associated with HPV infection and affects women across all reproductive age groups.

Any unexplained vaginal bleeding in a postmenopausal woman must be evaluated urgently to exclude malignancy, as the index of suspicion for endometrial or cervical cancer is high in this demographic.

Cervical Cancer

Cervical cancer is one of the most common gynecological malignancies worldwide. The most important risk factor is persistent infection with high-risk strains of human papillomavirus (HPV), particularly types 16 and 18, which is responsible for the vast majority of cervical cancers. Other risk factors include smoking, immunosuppression, multiple sexual partners, and early sexual debut.

Cervical cancer may present with:

• Postcoital bleeding (bleeding after sexual intercourse), one of the earliest and most characteristic symptoms.
• Irregular or intermenstrual bleeding.
• Postmenopausal bleeding.
• Watery or blood-tinged vaginal discharge with an offensive odor.
• Pelvic pain (in more advanced disease).

Regular cervical smear testing (Pap test) and HPV screening are the cornerstones of cervical cancer prevention and early detection. HPV vaccination, now recommended for both males and females, offers highly effective protection against the strains most commonly responsible for cervical cancer.

Endometrial Cancer

Endometrial cancer (cancer of the uterine lining) is the most common gynecological malignancy in high-income countries. It most frequently affects postmenopausal women, with a peak incidence between ages 60 and 70. The cardinal presenting symptom is postmenopausal vaginal bleeding, a symptom that should always prompt urgent investigation.

Risk factors include:

• Obesity (excess adipose tissue produces estrogen, which stimulates endometrial growth).
• Nulliparity (never having been pregnant).
• Late menopause.
• Diabetes mellitus and metabolic syndrome.
• Tamoxifen use (for breast cancer treatment).
• Hereditary non-polyposis colorectal cancer (Lynch syndrome).
• Unopposed estrogen therapy (estrogen without progesterone in postmenopausal HRT).

Ovarian Cancer

Ovarian cancer is often called the “silent killer” because it rarely causes symptoms in its early stages. Vaginal bleeding is not a typical presenting feature, but it can occur in advanced disease or in specific histological subtypes (such as granulosa cell tumors, which secrete estrogen and cause endometrial stimulation). More typically, ovarian cancer presents with vague abdominal discomfort, bloating, pelvic pressure, and urinary symptoms.

Vaginal and Vulvar Cancer

Vaginal cancer and vulvar cancer are rare but important causes of vaginal bleeding, particularly in older women. They may present as bleeding, ulceration, itching, or a visible mass. HPV infection is a risk factor for both, as is lichen sclerosus for vulvar cancer.

Uterine Sarcomas

Uterine sarcomas are rare malignant tumors arising from the muscular or connective tissue components of the uterus (as opposed to the endometrial glandular tissue). They may present with abnormal uterine bleeding, pelvic pain, and a rapidly enlarging uterus.

General Systemic Causes

A number of systemic diseases, affecting multiple organ systems, can cause vaginal bleeding as one of their manifestations:

• Coagulation disorders: These are conditions in which the blood’s ability to clot is impaired, leading to abnormal or excessive bleeding from various sites including the uterus. Examples include:

  • Hemophilia A and B: Hereditary deficiencies of clotting factors VIII and IX respectively; while X-linked and primarily affecting males, female carriers can experience menorrhagia.
  • Von Willebrand disease: The most common inherited bleeding disorder; affects both sexes and is a significant cause of menorrhagia in women.
  • Thrombocytopenia (low platelet count): Can result from immune thrombocytopenic purpura (ITP), bone marrow suppression, medications, or systemic illness, and is a well-recognized cause of menorrhagia.

• Leukemias and lymphomas: Hematological malignancies can cause thrombocytopenia through bone marrow infiltration and suppression of normal platelet production, leading to abnormal bleeding including from the uterus.

• Hepatic insufficiency: The liver produces the majority of clotting factors. In severe liver disease, clotting factor synthesis is impaired, leading to a coagulopathy that can cause or exacerbate abnormal uterine bleeding.

• Renal insufficiency: Chronic kidney disease causes platelet dysfunction (uremic platelet dysfunction), which can contribute to abnormal bleeding including menorrhagia.

• Hypothyroidism: Thyroid hormone deficiency impairs coagulation and may cause menorrhagia through multiple mechanisms, including effects on the coagulation cascade and on ovarian function. Hyperthyroidism can also disturb menstrual regularity.

Causes by Age Group

One of the most clinically useful frameworks for approaching vaginal bleeding is stratifying the differential diagnosis by the patient’s age group, as the likelihood of different causes varies dramatically across the life cycle.

Infancy and Childhood (Before Menarche)

Vaginal bleeding in a prepubertal child, before the first menstrual period (menarche), must always be investigated thoroughly, as normal physiological bleeding does not occur before puberty. Possible causes include:

• Vulvovaginitis: Inflammation or infection of the vulva and vagina. This is the most common cause of vaginal complaints in prepubertal girls.
• Vaginal foreign body: A child may insert a foreign object into the vagina, which can cause local injury, infection, and bleeding.
• Accidental trauma: Straddle injuries or other accidental genital trauma.
• Vaginal neoplasms: Rare in childhood, but rhabdomyosarcoma (botryoid sarcoma) of the vagina is the most important malignancy to exclude.
• Precocious puberty: Early activation of the hypothalamic-pituitary-gonadal axis can cause early menstrual-like bleeding.
• Hormone-secreting tumors: Rare ovarian or adrenal tumors can produce estrogen, leading to uterine bleeding.
• Accidental ingestion of medications: Particularly estrogen-containing preparations (e.g., oral contraceptives belonging to a family member).
• Sexual abuse: Must always be considered when a child presents with unexplained genital trauma or bleeding, and must be managed with appropriate sensitivity, clinical expertise, and mandatory reporting protocols.

Adolescence

In adolescence, from menarche onward, the most common causes of abnormal bleeding reflect the hormonal immaturity of the adolescent reproductive axis:

• Anovulatory cycles: Very common in the first 1–2 years after menarche, while the hypothalamic-pituitary-ovarian axis matures and regular ovulatory cycles are established.
• PCOS: Often first manifests during adolescence with irregular periods, acne, and hirsutism.
• Coagulation disorders: Von Willebrand disease and other bleeding disorders frequently first come to clinical attention in adolescence, when heavy menstrual bleeding begins.
• Pregnancy: Including ectopic pregnancy and miscarriage. Pregnancy must always be considered and excluded in any adolescent with vaginal bleeding.
• Sexually transmitted infections: Cervicitis secondary to chlamydia or gonorrhea is a common and under-recognized cause of intermenstrual bleeding in sexually active adolescents.
• Sexual abuse: Remains a consideration, particularly in younger adolescents.

Reproductive Age (Approximately 18–45 Years)

This is the most clinically complex age group, as the differential diagnosis is widest:

• Menorrhagia (heavy menstrual bleeding) is the most common presenting pattern, most frequently caused by uterine fibroids, adenomyosis, endometrial polyps, or anovulatory cycles.
• Benign organic pathologies, particularly uterine fibroids and polyps, are the dominant structural causes.
• Pregnancy-related bleeding: Must always be considered and excluded with a pregnancy test in any woman of reproductive age.
• Hormonal contraception: Breakthrough bleeding from pills, patches, rings, or IUDs is common.
• STIs and pelvic inflammatory disease: Remain important causes, particularly in younger women.
• Endometriosis: A common and often under-diagnosed cause of dysmenorrhea and abnormal bleeding.

Perimenopause

As women approach menopause, the risk of organic malignant pathology increases significantly, and must be given serious consideration in the evaluation of any perimenopausal woman with abnormal uterine bleeding:

• Endometrial cancer risk increases substantially from the late perimenopausal period onward.
• Irregular ovulatory cycles and anovulation are common as ovarian function declines, causing erratic and sometimes heavy bleeding.
• Uterine fibroids may temporarily enlarge due to perimenopausal hormonal fluctuations before shrinking after menopause.

Any irregular, unpredictable, or heavy bleeding in a perimenopausal woman should prompt endometrial biopsy or hysteroscopic evaluation to exclude malignancy.

Postmenopause

Any vaginal bleeding occurring more than 12 months after the last menstrual period is classified as postmenopausal bleeding and must be presumed to be of malignant origin until proven otherwise.

Fortunately, in practice, the majority of postmenopausal bleeding has benign causes:

• Endometrial atrophy: The thinned, fragile postmenopausal endometrium can bleed with minimal provocation. This is the most common cause of postmenopausal bleeding overall.
• Vaginal atrophy (genitourinary syndrome of menopause): Reduced estrogen leads to thinning and fragility of the vaginal epithelium, which can cause bleeding, particularly after intercourse.
• Endometrial polyps: Benign polyps can persist into the postmenopausal period and cause spotting.
• Hormone replacement therapy (HRT): Women on cyclical HRT may have planned withdrawal bleeds; those on continuous combined HRT may experience breakthrough bleeding, particularly in the first few months.
• Endometrial cancer: While less common than benign causes in absolute terms, it is the most important diagnosis to exclude and is found in approximately 10% of women investigated for postmenopausal bleeding.

---

Symptoms

As noted in the introduction, vaginal bleeding may present as an isolated symptom or may be accompanied by other manifestations that reflect the underlying pathology. The most clinically important associated symptoms include:

• Abdominal or pelvic pain: Can indicate dysmenorrhea, ovulatory pain, endometriosis, pelvic inflammatory disease, ectopic pregnancy, or ovarian cyst rupture. The character, location, and timing of the pain provide important diagnostic clues.

• Vaginal discharge: An abnormal discharge accompanying bleeding suggests a genital infection (bacterial vaginosis, STI) or a cervical lesion. The color, odor, and consistency of the discharge are clinically relevant.

• Fatigue and general malaise: Non-specific but may indicate chronic blood loss causing anemia, systemic infection, or malignancy.

• Nausea and vomiting: In a woman of reproductive age, these symptoms alongside bleeding raise the possibility of pregnancy complications, particularly ectopic pregnancy or miscarriage. Severe, persistent nausea may also be a feature of gestational trophoblastic disease.

• Pallor and tachycardia: These signs indicate significant acute blood loss or chronic iron-deficiency anemia secondary to prolonged heavy bleeding. Iron deficiency anemia reduces hemoglobin and red blood cell counts and may require specific iron supplementation or, in severe cases, blood transfusion.

• Weight loss and night sweats: Constitutional symptoms that, combined with abnormal bleeding, raise concern for malignancy.

• Urinary or bowel symptoms: Can indicate advanced gynecological malignancy invading adjacent structures.

---

Diagnosis

The diagnostic workup for vaginal bleeding combines a thorough clinical history and physical examination with targeted investigations, guided by the clinical picture, the patient’s age, and the characteristics of the bleeding.

Clinical History

The clinician, typically a gynecologist, will conduct a structured interview to characterize:

• Bleeding pattern: Is it regular (cyclical) or irregular? Is it heavy or light? How long has it been occurring?
• Menstrual history: Age of menarche, cycle regularity, duration and heaviness of normal periods, date of last menstrual period.
• Obstetric history: Number of pregnancies and deliveries, current pregnancy status (a pregnancy test should always be performed in women of reproductive age).
• Sexual history: Contraceptive use, sexual activity, history of STIs.
• Associated symptoms: Pain, discharge, systemic symptoms.
• Medications: Particularly hormonal preparations, anticoagulants, or medications that may affect the uterus.
• Family history: Gynecological malignancies, coagulation disorders.
• Medical history: Metabolic diseases, thyroid disorders, liver or kidney disease.

A key clinical principle: if the bleeding is regular and cyclical, it is more likely to reflect a benign organic lesion (such as a fibroid) or anovulation. If the bleeding is irregular and unpredictable, a malignant cause must be higher on the differential diagnosis.

Pregnancy Exclusion

In any woman of reproductive age presenting with vaginal bleeding, the first and essential step is to exclude pregnancy with a pregnancy test. This applies even when the patient does not believe she could be pregnant, as ectopic pregnancies and unrecognized very early pregnancies are well-documented clinical realities.

Physical and Gynecological Examination

A pelvic examination, including speculum inspection of the vagina and cervix, and bimanual palpation of the uterus and adnexa, provides critical information about the source and likely cause of the bleeding.

Laboratory Investigations

• Complete blood count (CBC): To detect anemia (reduced hemoglobin, hematocrit, and red blood cell count) resulting from blood loss, which may require treatment in its own right.
• Coagulation studies: Prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet count, to screen for bleeding disorders.
• Thyroid function tests: TSH and free T4, to exclude hypothyroidism or hyperthyroidism as a contributing cause.
• Pregnancy test (serum beta-hCG): More sensitive than urine tests and quantitative, it is essential for detecting early and ectopic pregnancies.
• STI testing: Cervical swabs or nucleic acid amplification tests (NAATs) for chlamydia, gonorrhea, and other pathogens.
• Hormonal profile: FSH, LH, estradiol, progesterone, prolactin, testosterone, and DHEA-S, when endocrine dysfunction (PCOS, premature ovarian insufficiency, hyperprolactinemia) is suspected.

Imaging

• Transvaginal ultrasound (TVUS): The gold-standard first-line imaging modality for the investigation of abnormal uterine bleeding. TVUS provides excellent visualization of the uterus (including the endometrial thickness and morphology) and ovaries, and can identify fibroids, polyps, adenomyosis, endometrial thickening, ovarian cysts, and other structural abnormalities. It is safe, well-tolerated, widely available, and does not use ionizing radiation.
• Saline infusion sonography (SIS) / sonohysterography: Transvaginal ultrasound performed while sterile saline is infused into the uterine cavity. This technique dramatically improves the detection of intracavitary lesions such as polyps and submucosal fibroids.
• CT scan of the abdomen and pelvis: Useful for staging known or suspected malignancy and for evaluating complex pelvic masses.
• Pelvic MRI: Provides superior soft-tissue contrast compared to ultrasound and CT. Particularly valuable for characterizing uterine fibroids and adenomyosis, evaluating the extent of endometrial or cervical cancer, and investigating complex ovarian masses.

Endoscopic and Histological Investigations

• Hysteroscopy: Direct visualization of the uterine cavity using a thin, lighted telescope inserted through the cervix. Hysteroscopy is the most accurate method for diagnosing intracavitary pathology (polyps, submucosal fibroids, endometrial cancer) and can be combined with directed biopsy, taking tissue samples from abnormal areas for histological examination.
• Endometrial biopsy: Sampling of the endometrial lining through the cervix, either in the office (using a thin aspiration device) or during hysteroscopy. This is essential in postmenopausal women, in perimenopausal women with irregular bleeding, and in any case where endometrial malignancy cannot be excluded by imaging alone. The tissue sample is sent for histopathological analysis.
• Colposcopy and cervical biopsy: If an abnormal cervical lesion is identified (or if HPV testing or cervical cytology is abnormal), colposcopy, examination of the cervix under magnification, and targeted biopsies of abnormal areas are performed.

---

Treatment and Remedies

The treatment of vaginal bleeding is entirely dependent on its underlying cause, as well as the patient’s age, reproductive goals, overall health status, and personal preferences. A shared decision-making approach, in which the woman is actively involved in choosing among available treatment options, is both ethically appropriate and practically effective, as it improves treatment adherence and outcomes.

Watchful Waiting and Lifestyle Modification

For mild, infrequent spotting attributable to benign causes such as stress, minor hormonal fluctuations, or adjustment to a new contraceptive, reassurance and monitoring may be the most appropriate initial approach. Lifestyle modifications that may help include:

• Stress management: Mindfulness, regular exercise, psychological support, adequate sleep.
• Dietary optimization: Adequate caloric and micronutrient intake (particularly iron, to prevent or treat deficiency anemia), particularly important in women with eating disorders or restrictive diets.
• Weight management: Both obesity and low body weight can disrupt hormonal balance and contribute to abnormal bleeding.
• Smoking cessation: Smoking is associated with increased risk of several gynecological conditions.

Pharmacological Treatment

Medications used to manage abnormal uterine bleeding include:

• Hormonal therapies:

  • Combined oral contraceptive pill: Regulates the menstrual cycle, reduces endometrial proliferation, and decreases menstrual blood loss. Effective for dysfunctional uterine bleeding, PCOS, and endometriosis.
  • Progestins (progesterone analogues): Oral, injectable, or intrauterine (levonorgestrel-releasing IUD). The levonorgestrel IUD is one of the most effective treatments for menorrhagia, dramatically reducing menstrual blood loss.
  • GnRH analogues: Used to induce a temporary menopausal state, particularly to manage large fibroids before surgery or to relieve symptoms of severe endometriosis.
  • Selective progesterone receptor modulators (SPRMs): Ulipristal acetate has been used for medical management of uterine fibroids.

• Non-hormonal pharmacological treatments for menorrhagia:

  • Tranexamic acid: An antifibrinolytic agent that reduces menstrual blood loss by inhibiting the breakdown of blood clots within the uterine vasculature. Taken only during menstruation.
  • Non-steroidal anti-inflammatory drugs (NSAIDs): Such as mefenamic acid or ibuprofen; reduce prostaglandin-mediated vasodilation in the endometrium and decrease blood loss, while also relieving dysmenorrhea.

• Treatment of underlying systemic conditions:

  • Thyroid hormone replacement for hypothyroidism.
  • Insulin-sensitizing agents (metformin) and anti-androgenic therapies for PCOS.
  • Coagulation factor replacement or desmopressin for Von Willebrand disease.
  • Platelet transfusions or immunosuppressive therapy for thrombocytopenia.

• Antibiotics: For genital infections (chlamydia, gonorrhea, PID), with selection based on the identified or suspected pathogen.

• Iron supplementation: To treat iron-deficiency anemia secondary to chronic blood loss. In severe cases, intravenous iron or blood transfusion may be required.

Surgical Treatment

Surgery is indicated when pharmacological management fails, when a structural lesion (fibroid, polyp) is causing bleeding that is refractory to medical therapy, or when malignancy is diagnosed:

• Hysteroscopic polypectomy or myomectomy: Removal of endometrial polyps or submucosal fibroids through the hysteroscope, without external incisions. A minimally invasive and highly effective procedure for these specific pathologies.
• Laparoscopic or abdominal myomectomy: Surgical removal of uterine fibroids while preserving the uterus, appropriate for women who wish to retain fertility.
• Endometrial ablation: Destruction of the endometrial lining using heat, radiofrequency energy, or other modalities. Highly effective for menorrhagia in women who have completed their family and do not wish to preserve fertility. Not suitable for women who may wish to become pregnant.
• Uterine artery embolization (UAE): A minimally invasive radiological procedure in which the blood supply to uterine fibroids is blocked, causing them to shrink. An alternative to surgery for selected patients.
• Hysterectomy (surgical removal of the uterus): The definitive treatment for menorrhagia when all other options have failed or are inappropriate, or when malignancy of the uterus is diagnosed. Can be performed laparoscopically, robotically, or by open abdominal surgery.
• Oncological surgery: Radical hysterectomy (for early cervical and endometrial cancer), bilateral salpingo-oophorectomy (removal of fallopian tubes and ovaries), and lymph node dissection, performed by gynecological oncologists as part of a comprehensive cancer treatment plan that may also include radiation therapy and chemotherapy.

The Role of Shared Decision-Making

The choice of treatment must always be tailored to the individual woman’s circumstances. Key considerations include:

• Age: A 25-year-old with uterine fibroids and a strong desire for future pregnancy requires a completely different approach from a 55-year-old postmenopausal woman with the same finding.
• Reproductive goals: Fertility-preserving options are prioritized for women who have not yet completed their family.
• Symptom severity: The impact of bleeding on quality of life, including anemia, pain, and psychological burden, informs the aggressiveness of treatment.
• Patient preferences: Some women strongly prefer to avoid surgery; others find ongoing medical management burdensome. These preferences are valid and should guide clinical decision-making.
• Comorbidities and surgical risk: Medical conditions that increase surgical risk may favor conservative management.

Active participation of the patient in decisions about her own care, informed by clear, honest, and compassionate communication from her healthcare team, is associated with better adherence to treatment plans and ultimately with better clinical outcomes.

---

Frequently Asked Questions

What is vaginal spotting?

Spotting refers to very light vaginal bleeding outside of the normal menstrual period, typically just a few drops or a light smear of blood noticed on underwear or toilet paper. It can be pinkish, brownish, or bright red. While it is lighter than a menstrual period, it should be evaluated by a healthcare provider, particularly if it is recurrent or unexplained.

What causes spotting between periods?

The most common causes of mid-cycle spotting include hormonal contraceptive use (particularly in the first months), ovulation (some women notice light spotting at the time of ovulation, known as “mittelschmerz spotting”), stress, and hormonal imbalances. Less commonly, spotting may indicate uterine fibroids, polyps, endometritis, cervical ectropion, or, particularly in older women, malignancy.

Should I see a doctor about spotting?

Yes. Any bleeding outside of the expected menstrual period, whether light spotting or heavier bleeding, warrants medical evaluation, particularly if it is new, recurrent, or associated with other symptoms such as pain, discharge, or systemic complaints.

Is spotting during early pregnancy normal?

Light spotting in the first trimester of pregnancy is common and often benign, as it may represent implantation bleeding or be related to increased cervical vascularity. However, any bleeding during pregnancy should be reported to a healthcare provider promptly, as it can also indicate a threatened miscarriage, ectopic pregnancy, or other complication.

What does postmenopausal bleeding mean?

Any vaginal bleeding occurring more than 12 months after the last menstrual period is classified as postmenopausal bleeding and must be investigated urgently to exclude endometrial cancer, cervical cancer, or other malignancy. While the majority of postmenopausal bleeding has benign causes (endometrial atrophy, polyps), malignancy must always be excluded through appropriate investigation.

Can stress cause vaginal bleeding?

Yes. Chronic psychological or physical stress can disrupt the hormonal axis that regulates the menstrual cycle, leading to anovulatory cycles and intermenstrual bleeding. Stress is recognized as one of the most common benign causes of mid-cycle spotting in otherwise healthy women.

What investigations are done for vaginal bleeding?

The key investigation is transvaginal ultrasound, which allows direct visualization of the uterus and ovaries. A pregnancy test is always performed in women of reproductive age. Blood tests assess for anemia, coagulation disorders, thyroid function, and hormonal imbalances. In selected cases, hysteroscopy with endometrial biopsy is performed to directly examine the uterine cavity and sample the endometrial lining for histological analysis.

---

Sources and Bibliography

• Bolis G. et al. Manuale di Ginecologia ed Ostetricia. Naples: Edises srl; 2011.
• Munro MG, Critchley HO, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years. Int J Gynaecol Obstet. 2018;143(3):393-408.
• National Institute for Health and Care Excellence (NICE). Heavy menstrual bleeding: assessment and management. NICE Guideline NG88. 2018 (updated 2021). Available at: www.nice.org.uk
• American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 128: Diagnosis of Abnormal Uterine Bleeding in Reproductive-Aged Women. Obstet Gynecol. 2012;120(1):197-206.
• World Health Organization (WHO). Selected practice recommendations for contraceptive use. 3rd ed. Geneva: WHO; 2016.
• Goldstein SR. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. Menopause. 2011;18(1):11-8.